ES2196063T3 - Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. - Google Patents

Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.

Info

Publication number
ES2196063T3
ES2196063T3 ES95919986T ES95919986T ES2196063T3 ES 2196063 T3 ES2196063 T3 ES 2196063T3 ES 95919986 T ES95919986 T ES 95919986T ES 95919986 T ES95919986 T ES 95919986T ES 2196063 T3 ES2196063 T3 ES 2196063T3
Authority
ES
Spain
Prior art keywords
hemorragies
medicines
treatment
progesterone
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919986T
Other languages
English (en)
Inventor
Kristof Chwalisz
Klaus Stockemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2196063T3 publication Critical patent/ES2196063T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS ANTAGONISTAS DE PROGESTERONA COMPETITIVOS (ANTIGESTAGENOS) SON IDONEOS PARA LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE HEMORRAGIAS UTERINAS DISFUNCIONALES (METRORRAGIAS, MENORRAGIAS, HIPERMENORREAS).
ES95919986T 1995-02-02 1995-02-02 Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. Expired - Lifetime ES2196063T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (1)

Publication Number Publication Date
ES2196063T3 true ES2196063T3 (es) 2003-12-16

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919986T Expired - Lifetime ES2196063T3 (es) 1995-02-02 1995-02-02 Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.

Country Status (20)

Country Link
US (1) US6451780B1 (es)
EP (1) EP0806952B1 (es)
JP (1) JPH10512889A (es)
KR (1) KR100370908B1 (es)
AT (1) ATE235907T1 (es)
AU (1) AU714959B2 (es)
CA (1) CA2186953C (es)
DE (1) DE59510626D1 (es)
DK (1) DK0806952T3 (es)
ES (1) ES2196063T3 (es)
FI (1) FI117850B (es)
HU (1) HU226276B1 (es)
MX (1) MX9603889A (es)
NO (1) NO964155L (es)
NZ (1) NZ287024A (es)
PL (1) PL316533A1 (es)
PT (1) PT806952E (es)
SK (1) SK282570B6 (es)
UA (1) UA37259C2 (es)
WO (1) WO1996023503A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747710B2 (en) * 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ES2295050T3 (es) 1999-08-31 2008-04-16 Bayer Schering Pharma Aktiengesellschaft Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
SI2148681T1 (sl) 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
UA37259C2 (uk) 2001-05-15
KR970704451A (ko) 1997-09-06
HUT75930A (en) 1997-05-28
MX9603889A (es) 1997-04-30
JPH10512889A (ja) 1998-12-08
ATE235907T1 (de) 2003-04-15
AU714959B2 (en) 2000-01-13
EP0806952B1 (de) 2003-04-02
SK121996A3 (en) 1997-05-07
FI963049L (fi) 1996-10-01
SK282570B6 (sk) 2002-10-08
FI963049A0 (fi) 1996-08-01
EP0806952A1 (de) 1997-11-19
CA2186953A1 (en) 1996-08-08
WO1996023503A1 (de) 1996-08-08
FI117850B (fi) 2007-03-30
KR100370908B1 (ko) 2003-04-10
HU9602668D0 (en) 1996-11-28
NO964155D0 (no) 1996-10-01
CA2186953C (en) 2009-11-10
US6451780B1 (en) 2002-09-17
DE59510626D1 (de) 2003-05-08
HU226276B1 (en) 2008-07-28
AU2561195A (en) 1996-08-21
NZ287024A (en) 2001-03-30
DK0806952T3 (da) 2003-06-16
PL316533A1 (en) 1997-01-20
PT806952E (pt) 2003-08-29
NO964155L (no) 1996-10-01

Similar Documents

Publication Publication Date Title
DK0806952T3 (da) Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
AR017296A1 (es) Uso de un antagonista del receptor de 5-hidroxitriptamina y compuestos antagonistas
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
NO994850L (no) Farmakologiske midler
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
BR9909486A (pt) Compostos calcilìticos
DK1764111T3 (da) Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
IT1270612B (it) Derivati eterociclo-condensatori di morfinoidi
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
ES2152948T3 (es) Derivados de imidazol, triazol y tetrazol.
SE9702794D0 (sv) New compounds
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
IT1215325B (it) Composti antagonisti di recettori -h2 e procedimento per la loro preparazione.
IT1295356B1 (it) Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3
NO912497D0 (no) Doseringsform for administrering av kalsiumantagonist.
NO890502L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.
NO891678L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.
MX9301870A (es) Antagonistas receptores de angiotensina ii
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande